Sorrento Therapeutics Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sorrento Therapeutics Inc

SRNE 0.00180

0.0%

Dec 22 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Julius Wong	9/17/2020 5:59:54 AM
	of 171

Sorrento gets FDA nod for early-stage COVID-19 antibody trial Sep. 17, 2020 12:33 AM ET\|About: Sorrento Therapeutics, Inc. (SRNE)\|By: Mamta Mayani, SA News Editor Sorrento Therapeutics (NASDAQ: SRNE) receives FDA clearance to its Phase 1 clinical trial for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients. The STI-1499 clinical program is being designed for rapid adaptive expansion, including international sites in Brazil to supplement the US program. The initial trial is expected to enroll rapidly and is expected to be followed by large trials targeting a potential Emergency Use Authorization (EUA) submission before year. Previously, in preclinical studies, STI-1499 demonstrated 100% in vitro neutralizing effect against SARS-CoV-2, preventing infection of healthy cells. Animal data generated in Syrian Golden hamsters infected with SARS-CoV-2 was presented to the FDA in support of a post-exposure human treatment dose for the IND. seekingalpha.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next